Dilaudid-HP

See also: Generic Dilaudid

Dilaudid-HP is a brand name of hydromorphone, approved by the FDA in the following formulation(s):

DILAUDID-HP (hydromorphone hydrochloride - injectable; injection)

• 
  Manufacturer: PURDUE PHARM PRODS
  
  Approval date: January 11, 1984
  
  Strength(s): 10MG/ML ^[RLD][AP]


• 
  Manufacturer: PURDUE PHARM PRODS
  
  Approval date: August 4, 1994
  
  Strength(s): 250MG/VIAL ^[RLD]

Has a generic version of Dilaudid-HP been approved?

A generic version of Dilaudid-HP has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Dilaudid-HP and have been approved by the FDA:

hydromorphone hydrochloride injectable; injection

• 
  Manufacturer: AKORN
  
  Approval date: April 14, 2010
  
  Strength(s): 10MG/ML ^[AP], 10MG/ML ^[AP]


• 
  Manufacturer: BARR
  
  Approval date: April 25, 2003
  
  Strength(s): 10MG/ML ^[AP]


• 
  Manufacturer: HOSPIRA
  
  Approval date: June 19, 1997
  
  Strength(s): 10MG/ML ^[AP]


• 
  Manufacturer: HOSPIRA INC
  
  Approval date: June 17, 2008
  
  Strength(s): 10MG/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dilaudid-HP. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Hydromorphone and hydrocodone compositions and methods for their synthesis
  Patent 6,589,960
  Issued: July 8, 2003
  Inventor(s): William H.; Harclerode & Robert; Gault & Mark D.; Sandison
  Assignee(s): Abbott Laboratories
  A method for the preparation of a ketone from a narcotic alkaloid having an allyl alcohol moiety is disclosed. The method includes mixing the narcotic alkaloid with an acid in the presence of a catalyst wherein the method is carried out in the substantial absence of hydrogen gas. The method is useful for preparing hydromorphone and hydrocodone compositions having novel impurity profiles. Compositions comprising hydromorphone and hydrocodone are also disclosed.
  
  Patent expiration dates:
  
  
  • November 9, 2020
    
    ✓ 
    Drug product
  
  

See also...

• Dilaudid-HP Consumer Information (Wolters Kluwer)
• Dilaudid-HP injection Consumer Information (Cerner Multum)
• Dilaudid-HP Advanced Consumer Information (Micromedex)
• Hydromorphone Consumer Information (Wolters Kluwer)
• Hydromorphone Extended-Release Consumer Information (Wolters Kluwer)
• Hydromorphone Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Hydromorphone High-Potency Consumer Information (Wolters Kluwer)
• Hydromorphone Liquid Consumer Information (Wolters Kluwer)
• Hydromorphone Suppository Consumer Information (Wolters Kluwer)
• Hydromorphone Tablets Consumer Information (Wolters Kluwer)
• Hydromorphone Consumer Information (Cerner Multum)
• Hydromorphone injection Consumer Information (Cerner Multum)
• Hydromorphone rectal Consumer Information (Cerner Multum)
• Hydromorphone Advanced Consumer Information (Micromedex)
• Hydromorphone Injection Advanced Consumer Information (Micromedex)
• Hydromorphone Hydrochloride AHFS DI Monographs (ASHP)